Glass Lewis Recommends Shareholders Vote 'FOR' Hanmi Pharmaceutical Acquisition

summarizeSummary

This filing announces that Glass Lewis, a prominent independent proxy advisory firm, has recommended that Aptose Biosciences shareholders approve the proposed acquisition by Hanmi Pharmaceutical. This follows a similar recommendation from ISS, as disclosed in a recent filing. The endorsement from another major proxy advisor significantly strengthens the likelihood of shareholder approval for the acquisition and the associated continuance, moving the company closer to completing this major corporate transaction. Shareholders are reminded to vote by the March 27, 2026 deadline for the reconvened special meeting on March 31, 2026.

check_boxKey Events

• Glass Lewis Endorses Acquisition

  Glass, Lewis & Co., a leading independent proxy advisory firm, has recommended that Aptose shareholders vote 'FOR' the special resolution to approve the previously announced arrangement with Hanmi Pharmaceutical Co. Ltd.

• Shareholder Meeting and Voting Deadline Reminder

  Shareholders are reminded to submit their proxies by 11:00 a.m. (EST) on Friday, March 27, 2026, for the special meeting reconvened to March 31, 2026, to vote on the Arrangement and a Continuance.

• Board Recommendation Reaffirmed

  Aptose's Special Transaction Committee and Board of Directors unanimously recommend that shareholders vote 'FOR' the special resolutions approving the Continuance and the Arrangement.

auto_awesomeAnalysis

This filing announces that Glass Lewis, a prominent independent proxy advisory firm, has recommended that Aptose Biosciences shareholders approve the proposed acquisition by Hanmi Pharmaceutical. This follows a similar recommendation from ISS, as disclosed in a recent filing. The endorsement from another major proxy advisor significantly strengthens the likelihood of shareholder approval for the acquisition and the associated continuance, moving the company closer to completing this major corporate transaction. Shareholders are reminded to vote by the March 27, 2026 deadline for the reconvened special meeting on March 31, 2026.